Barclays’s Marker Therapeutics MRKR Stock Holding History

Barclays’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93	Buy	+63	New	+$92	﹤0.01%	5198
2021 Q3	–	Sell	-339	Closed	-$9K	–	4906
2021 Q2	$9K	Buy	+339	New	+$8.93K	﹤0.01%	4676
2020 Q3	–	Sell	-2,530	Closed	-$53K	–	5438
2020 Q2	$53K	Buy	+2,530	New	+$55.3K	﹤0.01%	4904
2020 Q1	–	Sell	-2,710	Closed	-$78K	–	6348
2019 Q4	$78K	Buy	+2,710	New	+$98.6K	﹤0.01%	5588
2019 Q3	–	Sell	-2,797	Closed	-$221K	–	6977
2019 Q2	$221K	Sell	2,797 -10,262	-79%	-$610K	﹤0.01%	5018
2019 Q1	$862K	Sell	13,059 -2,953	-18%	-$172K	﹤0.01%	3567
2018 Q4	$889K	Buy	16,012 +15,432	+2,661%	+$1.12M	﹤0.01%	3244
2018 Q3	$52K	Sell	580 -220	-28%	-$18.9K	﹤0.01%	6057
2018 Q2	$75K	Buy	+800	New	+$40.8K	﹤0.01%	5422
2018 Q1	–	Hold	0	–	–	–	7230

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Barclays's MRKR Position: Q2 2026 in Review

Barclays opened a new position in Marker Therapeutics (MRKR) in Q2 2026: 63 shares worth $93. The stake represents ﹤0.01% of the portfolio and ranks #5198 among its holdings. This is a return to the name: Barclays previously reported a position in MRKR as recently as Q2 2021.

Barclays first reported a position in MRKR in Q2 2018 and has held it in 9 quarters since. The position peaked at $889K in Q4 2018. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

Barclays held 63 shares of Marker Therapeutics worth $93 as of Q2 2026.
Marker Therapeutics was a new Barclays position in Q2 2026.
Marker Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5198 holding.
Barclays first reported a position in Marker Therapeutics in Q2 2018 and has held it in 9 quarters since.
Barclays's Marker Therapeutics position peaked at $889K in Q4 2018.
35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.